University of South Florida

Digital Commons @ University of South Florida
Nursing Faculty Publications

College of Nursing

2013

Epigenetics in Critical Illness: A New Frontier
Brian T. Graves
University of South Florida

Cindy L. Munro
University of South Florida

Follow this and additional works at: https://digitalcommons.usf.edu/nur_facpub

Scholar Commons Citation
Graves, Brian T. and Munro, Cindy L., "Epigenetics in Critical Illness: A New Frontier" (2013). Nursing
Faculty Publications. 190.
https://digitalcommons.usf.edu/nur_facpub/190

This Article is brought to you for free and open access by the College of Nursing at Digital Commons @ University
of South Florida. It has been accepted for inclusion in Nursing Faculty Publications by an authorized administrator
of Digital Commons @ University of South Florida. For more information, please contact
scholarcommons@usf.edu.

Hindawi Publishing Corporation
Nursing Research and Practice
Volume 2013, Article ID 503686, 5 pages
http://dx.doi.org/10.1155/2013/503686

Review Article
Epigenetics in Critical Illness: A New Frontier
Brian T. Graves and Cindy L. Munro
College of Nursing, University of South Florida, 12091 Bruce B. Downs Boulevard, MDC22, Tampa, FL 33612-4766, USA
Correspondence should be addressed to Cindy L. Munro; cmunro2@health.usf.edu
Received 17 April 2013; Accepted 16 June 2013
Academic Editor: Susan Dorsey
Copyright © 2013 B. T. Graves and C. L. Munro. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Epigenetics is the study of alterations in the function of genes that do not involve changes in the DNA sequence. Within the
critical care literature, it is a relatively new and exciting avenue of research in describing pathology, clinical course, and developing
targeted therapies to improve outcomes. In this paper, we highlight current research relative to critical care that is focused within the
major epigenetic mechanisms of DNA methylation, histone modification, microRNA regulation, and composite epigenetic scoring.
Within this emerging body of research it is quite clear that the novel therapies of the future will require clinicians to understand
and navigate an even more complex and multivariate relationship between genetic, epigenetic, and biochemical mechanisms in
conjunction with clinical presentation and course in order to significantly improve outcomes within the acute and critically ill
population.

1. Introduction
Critical care practice is beginning to look toward more
specific cellular, biochemical, and genetic interventions in
order to make a significant impact on patient outcomes. In
addition to the extensive cellular, biochemical, and genetic
body of research in process today, the science of epigenetics
has become a more frequent focus within the critical care
literature over the past 5+ years.
Though epigenetics may appear to be relatively new to us
in the critical care discipline, it has actually been studied for
over 70 years and was first described by Conrad Waddington
in 1942 as “the branch of biology which studies the casual
interactions between genes and their products, which bring
the phenotype into being” [1, 2]. In simpler terms, epigenetics
is the study of changes in the function of genes that do
not involve changes in the DNA sequence. It is the study of
how the same sequence of DNA can produce significantly
different phenotypes as a result of differing biochemical
changes that alter gene availability for protein production
[1, 3]. What makes this even more fascinating than a nature
versus nurture discussion is that there are a small number of
known genes in which specific biochemical modifications can
impact the phenotype of offspring and are thus inheritable
yet do not alter base pair sequencing of DNA. This is termed
DNA imprinting [3]. A classic example of this is seen on

chromosome 15 in Angelman and Prader-Willi syndromes
where DNA methylation is involved in genomic imprinting
of parental germ line cells, impacting the phenotype of the
offspring depending upon whether the affected chromosome
is paternal or maternal in origin [4–6]. Children with PraderWilli syndrome inherit an affected paternal chromosome 15,
resulting in short stature, poor muscle tone, and hypogonadism; many of these children also have learning disabilities.
Children who inherit an affected maternal chromosome 15
may develop Angelman syndrome, which is associated with
developmental delays, ataxia; they also may have epilepsy and
microcephaly.
Of even more importance to critical care, epigenetic
changes of somatic cells can be propagated to progeny of
those cells within an individual, impacting phenotypic expression during the course of critical illness. For example,
epigenetic changes altering the effectiveness of immune cells
to respond to pathogens could persist in new immune cells
which inherited the epigenetic changes. These prior epigenetic changes could thus have a direct effect on an individual’s
ability to respond to sepsis in the future.
Interest in critical care has focused on DNA methylation, histone modification, and microRNA (miRNA). These
epigenetic mechanisms can result in increased or decreased
gene products. Decreased gene expression may result from
downregulation of genes (the transcription of RNA from
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specific gene sequences is inhibited or arrested). Increased
gene expression may result from upregulation of genes
(increased transcription of RNA from targeted genes). However, for genes which provide a messenger RNA (mRNA)
template for protein production, additional factors can influence the amount of protein produced from mRNA; for
example, how often each mRNA is used for transcription and
how quickly the mRNA is degraded can influence the amount
of protein produced. More specifically, DNA methylation (as
the result of enzymes known as DNA methylases) is the
attachment of methyl groups (CH3 ) to cytosine bases within
a DNA sequence; demethylation is removal of these methyl
groups. As the quantity and pattern of DNA methylation
increases, gene transcription into messenger RNA (mRNA)
decreases; demethylation can increase gene transcription.
Thus, DNA methylation represses expression of the affected
genes. Methylation patterns in DNA can be transmitted to
daughter cells during mitosis or transmitted to offspring as
a result of meiosis [1, 7, 8].
Furthermore, since DNA is an extremely long molecule,
it must be coiled and folded in order to fit into a nucleus
(Figure 1). Histones are the nuclear proteins that direct the
winding and coiling of DNA into nucleosomes and then
chromatin. Histone proteins have extremely long tails which
are susceptible to methylation, acetylation, ubiquitination,
phosphorylation, and so forth at multiple locations [7].
When histone tails are modified (histone modification), they
alter the way in which DNA will coil around a histone
octamer (four histones with DNA coiled around them to
form a nucleosome). The nucleosomes continue to fold and
coil into chromatin, and multiple chromatin coils create
a chromosome. In addition to gene sequence availability
being limited by DNA methylation, how tightly chromatin is
condensed will also impact the availability of gene sequences
to interact with transcription proteins in order for mRNA to
be transcribed and then translated into proteins [8, 9].
Epigenetic regulation can also occur through microRNAs (miRNAs). These small noncoding RNAs can act as
regulatory elements in both transcription and translation.
Noncoding RNAs are also involved in modifying phenotype
through various mechanisms, such as posttranscriptional and
transcriptional interference pathways, in which they may
alter chromatin and/or DNA methylation processes to further
stabilize gene silencing [1]. Roles for miRNAs in central
nervous system injury and in acute lung injury have been
postulated, although experimental evidence in critical care
subjects is lacking.
The extent of DNA methylation, histone modification,
and microRNA activity may impact the function of genes
without any alterations in the DNA sequence. These epigenetic mechanisms can have direct phenotypic implications.
Several intriguing examples have recently been highlighted
in critical care and are discussed below.

2. Epigenetics in Critical Care
When gene expression is altered, the potential for significant
phenotypical alterations to pathology, disease progression,
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and short- and long-term outcomes exists. Within critical
care, research regarding the influence of genetics is in its
early stages, and investigators are just beginning to look
toward the science of epigenetics for explanations for patient
and population differences in susceptibility to illness, clinical
course, and outcomes. In the following sections, specific
examples of epigenetic research focused on critical illness are
provided.
2.1. Methylation of DNA. Epigenetic regulation, in which
gene expression is altered and may significantly impact critical illness outcomes, can occur through direct methylation
of DNA cytosine bases resulting in downregulation of genes.
Alternatively, demethylation might upregulate expression of
genes. An example of downregulation through methylation
in acute illness has been associated with the pathological
processes associated with acute kidney injury (AKI) [11].
AKI is a common complication in critical care patients,
with an incidence greater than 5–10%, contributing to an
increase in morbidity and mortality. Previous animal studies
have suggested that altered expression of the KLK1 gene,
which results in the transcription/translation of the serine
protease kallikrein, may be related to AKI. Kallikrein is
involved in the biochemical reaction in the kidney to produce
kallidin, which pharmaceutically appears to have vasodilator
and natriuretic properties in animals. Additionally, increased
concentrations of kallikrein have been shown to be protective
in animals, diminishing renal cell death by apoptosis and
inflammation [11].
Kang and colleagues [11] prospectively compared hospitalized patients with established or incipient (early) AKI from
ischemia, nephrotoxins, sepsis, and other causes to healthy
nonhospitalized and ICU patient controls. In particular they
were looking for the increased methylation of the promoter
region of the KLK1 gene. The promoter region of a gene
is a DNA sequence where the enzyme RNA polymerase
binds to start mRNA transcription from the gene; the degree
and pattern of methylation of promoters can regulate gene
expression. Kang and colleagues hypothesized that gene
silencing by methylation of the KLK1 gene promoter and
thus the subsequent decrease of urine kallikrein may be
associated with established AKI. Contrary to their expected
findings, they found that established AKI patients, compared
to controls, had significantly greater DNA methylation of
KLK1 as expected but also had significantly higher levels of
urine excreted kallikrein, which was not expected. Interestingly, the established AKI patients also had significantly lower
average systolic blood pressure, increased heart rate, and
increased epinephrine concentrations. Epinephrine is known
to increase kallikrein concentrations in the urine, most likely
as part of the systemic regulation of hemodynamic instability
in acute illness.
Two significant contributions to the state of epigenetic
science in acute illness can be derived from the work of Kang
et al. [11]. First, it further advances our understanding of how
epigenetic modification may be trumped by other regulatory
mechanisms. Second, this study provides an expanded perspective of the complexity of system regulation, highlighting
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Epigenomic marks. the epigenome can mark DNA in two ways, both of which play a role in turning genes off or on. The first occurs when certain

chemical tags called methyl groups attach to the backbone of a DNA molecule. The second occurs when a variety of chemical tags attach to the
tails of histones, which are spool-like proteins that package DNA neatly into chromosomes. This action affects how tightly DNA is wound around
the histones.

Figure 1: Epigenetics marks (courtesy: National Human Genome Research Institute) [10]. This figure is obtained from http://www.genome
.gov/27532724.

the fact that even at the genetic level focusing on a single
targeted therapy solution may need to give way to other more
novel therapeutic approaches.
2.2. Histone Modification. Another type of epigenetic mechanism, histone acetylation, is now a potential therapeutic
target in critical illness. As previously discussed, DNA is
more or less accessible for transcription depending upon how
it is wound around histones in the nucleus. Acetylation of
histones occurs when acetyl groups are added to specific
amino acids (lysines) comprising the histones. Acetylation
of histones changes the availability of the DNA in that
area to transcription. Inhibitors of histone acetylation have
been examined in animal models of hemorrhagic shock and
LPS-induced sepsis; inhibiting histone acetylation reduces
immune responsiveness during the acute episode, and has
been associated with better outcomes [7]. Caution is warranted because not all cells respond similarly to pharmacologic agents targeted to histone modification, and acetylation
inhibitors affect cellular proteins in addition to histones.
Effects on nonhistone proteins may be positive, negative, or
neutral.

Although histone modifiers are currently being explored
as therapeutic agents, there is additional reason for caution
because of emerging evidence about the sequella of histone
modifications on immunity following sepsis. Patients who
survive sepsis have profound and long lasting immunosuppression which can impede appropriate response to
pathogens; 5- and 8-year survival is shorter compared to agematched people who have not had severe sepsis. Evidence
is accumulating that this consequence of critical illness is
associated with epigenetic changes in immune cells. In a
recent review of epigenetic mechanisms after sepsis, Carson
IV and colleagues [7] provided several possible examples.
Direct suppression of proinflammatory activity by epigenetic
mechanisms has been hypothesized as cause for lipopolysaccharide (LPS, a major component of Gram-negative bacterial
cell walls) tolerance. For example, in macrophages exposed
to LPS (either in the laboratory or in a patient experiencing
sepsis), an initial brisk proinflammatory response is followed
by histone modifications to promoter regions of interleukin I
beta and tumor necrosis factor alpha; these histone modifications reduce subsequent macrophage response to LPS resulting in immunosuppression. This has been demonstrated
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in animal models as well as in monocytes sampled from
critically ill patients.
2.3. MicroRNA. MiRNA is highly expressed in central nervous system tissues, and research suggests that they play a role
in neurodevelopment and neural plasticity [12]. Temporal
alterations in expression of miRNAs localized at areas of
central nervous system injury have been demonstrated in
rodent models of spinal cord injury, traumatic brain injury,
and brain ischemia [13, 14], although studies examining
miRNA in human trauma victims have not yet been reported.
Likely targets of these miRNAs have been identified by
computational analysis and computer modeling based on
sequence homology and include genes involved in inflammation and in neural signaling as well as other genes previously
identified as important in response to specific central nervous
system injuries. Madathil and colleagues [13] propose that in
the response to acute CNS injury, some miRNAs might have
a neuroprotective effect while others might have a neurotoxic
effect. Thus, the epigenetic regulation mediated by miRNAs
in the CNS is complex, and the effects in patients with CNS
trauma or cerebrovascular accident will likely be difficult to
be definitively determined.
MiRNAs contribute to differentiation and regulation of
the immune system and have been implicated in chronic pulmonary diseases with an inflammatory component, including
asthma, chronic obstructive pulmonary disease, and cystic
fibrosis [15]. There has been recent speculation that miRNAs
might also be involved in acute lung injury (ALI), including
acute respiratory distress syndrome (ARDS, the most severe
manifestation of ALI). Rodent models of ALI/ARDS, which
initiate acute injury by administration of LPS, have provided
some support for the involvement of miRNAs in the pathogenesis of ALI, but human data are not available.
Better understanding of the positive and negative effects
of miRNAs on the course of critical illness would be beneficial
in at least two ways. First, it would help to elucidate mechanisms underlying pathogenesis and protective response; this
could identify potential targets for pharmacotherapeutic or
nonpharmacotherapeutic interventions. Second, in the future
miRNAs could themselves be targets for intervention, with
a goal of enhancing regulatory effects related to protective
responses and suppressing regulatory effects associated with
pathogenesis.
2.4. Composite Scoring and Outcome Prediction. Warren and
colleagues [16] investigated whether epigenetic data could
improve on standard severity of illness scoring in trauma
patients. Both Acute Physiology, Age, and Chronic Health
Evaluation (APACHE) and Injury Severity Score (ISS) are
well-validated tools which are widely used in clinical practice
to score severity of illness [17, 18]. Building on the idea
that gene expression changes early in trauma and critical
illness might be prognostic of events occurring later in the
hospital course, gene expression data could provide a snapshot predictive of likely outcome. In order to examine this
concept, Warren and colleagues first developed a reference
gene expression profile from the leukocytes of 10 healthy
adults to calculate a reference score for each of 54,000 plus
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gene probe sets. Genomic response on the same gene probe
sets of critically ill adult subjects within the first 12 hours
of blunt trauma was compared to the healthy reference
values by calculating difference from reference for each gene
and then summing the differences, resulting in a difference
from reference (DFR) score for each subject. They found
that DFR scores, calculated early in the course of trauma,
were positively associated with important clinical outcomes
such as time on ventilator and length of stay. Since Warren
and colleagues examined a single time point 12 hours after
trauma, this study does not provide information about the
magnitude of genetic expression changes over time nor when
the optimal time to measure might be.
A second group of investigators [19] refined this approach
by retrospectively identifying 63 genes whose expression
varied in trauma subjects over the course of 28 days of
hospitalization and were significantly different between those
with complicated and uncomplicated recovery. Of the 63
genes, two-thirds were related to protective immunity and a
majority of those affected adaptive immunity. They found that
a newly developed commercial multiplex system to rapidly
quantify RNA (NanoString DFR, nanoString Technologies,
Seattle, WA) was a better predictor of complicated outcome (versus intermediate or uncomplicated outcome) than
standard microarrays, APACHE, or ISS score. Cuenca and
colleagues [19] noted that current technologies are limited by
the time required for processing samples; additional research
into rapid technologies will be necessary. They further suggest
that their data support a role for therapeutic agents that target
adaptive immunity and gene expression data as indicators of
likely response to biological response modifiers.
Interestingly, temporal gene expression patterns in dendritic cells of 10 patients over the first four days following
trauma identified upregulation of genes involved in antigen
presentation [20]. However, the gene expression in dendritic
cells was not associated with severity of illness scores. The
differential expression of genes between subsets of cells (such
as leukocytes and dendritic cells) and temporal changes
in expression within a cell subset complicates the ability
to develop predictive epigenetic measures of severity and
outcomes. Analogous to the “left shift” in a white blood cell
differential count, it may be essential to examine multiple
genetics expression profiles from multiple cell types simultaneously to fully understand response. Important predictive
patterns may emerge from such an approach, although
technical considerations preclude this approach in the clinical
setting at present.
Stratification by genetic risk profile could inform when
to initiate targeted therapy, who is most likely to benefit, and
whether patients are responding to prescribed therapies. This
information will be most useful if it can be assessed early in
the course of critical illness. However, the specific epigenetic
mechanisms underlying the changes in gene expression were
not elucidated in the above studies [16, 19, 20].

3. Conclusion
The state of the science in understanding the role of epigenetic
regulation as it relates to the pathology of critical illness,
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clinical course, and outcomes is evolving rapidly yet still well
within its infancy. Available research exists primarily within
the lab, animal, and preclinical realm and thus has yet to
be translated to the direct care of the critically ill person.
Epigenetic tools and methodologies continue to evolve and
improve, bringing the possibility of real time data to the point
of care for therapeutic intervention closer to reality. Better
identification and understanding of the role of epigenetic
modifications that are associated with the complex regulatory
and disregulatory processes of the disease state is essential
and it is apparent that our approach to therapeutically target
epigenetic modifications to improve outcomes may only be a
single component of even more complex novel therapies to
come.
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